

**Pharmacokinetics of the Port Delivery System with Ranibizumab in the Ladder
Phase 2 Trial for Neovascular Age-Related Macular Degeneration**

Charles C. Wykoff · Peter A. Campochiaro · Dante J. Pieramici · Arshad M. Khanani ·

Shamika Gune · Mauricio Maia · Matts Kågedal · Han Ting Ding · Katie F. Maass

Corresponding author

Charles C. Wykoff, MD, PhD, Retina Consultants of Texas, 4460 Bissonnet Street, Suite 200,
Bellaire, TX 77401. Tel: 713-524-3434. e-mail: charleswykoff@gmail.com

SUPPLEMENTARY MATERIAL**Table S1** Ladder PK-evaluable population and exclusions

	Port Delivery System with ranibizumab 10 mg/mL	Port Delivery System with ranibizumab 40 mg/mL	Port Delivery System with ranibizumab 100 mg/mL	Monthly intravitreal ranibizumab 0.5 mg
Full PK population	58	62	59	41
PK-evaluable population	16	25	27	N/A
Reasons for exclusion from PK-evaluable population				
Received intravitreal injections of ranibizumab in the study eye post Port Delivery System with ranibizumab implantation (including supplemental treatment)	14	5	6	N/A
Received intravitreal anti-VEGF in the fellow eye after first study treatment	23	26	18	9

PDS Phase 2 Ladder Trial PK Results

Ophthalmology and Therapy

Received bevacizumab in the study eye before first study treatment	14	10	12	8
Received bevacizumab in the fellow eye within 9 months before first study treatment	1	2	6	2

Because some patients could meet multiple reasons for exclusion from the PK-evaluable population, the summation of patients excluded for each reason does not equal the total number of patients excluded from the PK-evaluable population

N/A not applicable, *PK* pharmacokinetic, *VEGF* vascular endothelial growth factor




Fig. S1 Correlation of aqueous humor and serum ranibizumab concentrations in the pharmacokinetic-evaluable population. ^a Lowe J, et al. J Immunol Methods. 2018;461:44–52.

PDS Port Delivery System with ranibizumab




Fig. S2 Serum pharmacokinetic (PK) profiles of PK-evaluable patients in the Port Delivery System with ranibizumab (PDS) 10 mg/mL (**a**) and PDS 40 mg/mL (**b**) arms after implantation, first refill, and second refill. Vertical bars represent the geometric standard deviation. ^a Lowe J, et al. J Immunol Methods. 2018;461:44–52